This session will focus on recent advances in the understanding of multiple myeloma biology and the changes in the treatment of this disease after the introduction of the immunomodulatory drugs thalidomide and lenalidomide and the proteasome inhibitor bortezomib. The role of transplantation in the era of novel agents will be addressed, and future therapeutic directions will be discussed. This program will report on the most effective treatment strategies available today and outline how to properly integrate them in the management of multiple myeloma.
Dr. Gareth Morgan will review the biological features of multiple myeloma. He will describe the physiological immune system development, explain the mechanisms determining molecular alterations in myeloma, and correlate these abnormalities with the evolution of the disease. He will also comment on the clinical implications of these alterations in myeloma therapy.
Dr. S. Vincent Rajkumar will review the different doublet, triplet, or quadruplet drug combinations used for the treatment of newly diagnosed myeloma. He will provide efficacy and safety results of various studies and compare these approaches. He will also present preliminary results from recent studies introducing the concept of second-generation proteasome inhibitors.
Dr. Antonio Palumbo will review the role of stem cell transplantation in myeloma and the clinical benefit achieved after the introduction of novel induction, consolidation, and maintenance approaches. He will discuss whether drug combinations have replaced stem cell transplantation, the risk/benefit ratio of these approaches, and the role of maintenance treatment.